EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study

Abstract

Osimertinib is a third-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits EGFR TKI-sensitizing (EGFRm) and EGFR T790M resistance mutations, including CNS metastases. Osimertinib is the preferred first-line treatment in metastatic EGFRm NSCLC, approved as ≥second-line treatment in EGFRm NSCLC with T790M mutations, and approved as adjuvant treatment in resectable EGFRm NSCLC. This post-hoc analysis of AURA program and FLAURA trials reports for the first time, long-term safety data in EGFRm metastatic NSCLC treated with osimertinib 80 mg once-daily (QD) for ≥36 months.